Gentamicin B.braun

Leaflet accompanying the packaging: information for the user

Gentamicin B. BRAUN, 1 mg/ml, solution for infusion

Gentamicin B. BRAUN, 3 mg/ml, solution for infusion

Gentamicin

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any further questions, ask your doctor.
• If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Gentamicin B. Braun and what is it used for
• 2. Important information before using Gentamicin B. Braun
• 3. How to use Gentamicin B. Braun
• 4. Possible side effects
• 5. How to store Gentamicin B. Braun
• 6. Contents of the packaging and other information

1. What is Gentamicin B. Braun and what is it used for

Gentamicin B. Braun belongs to a group of antibiotics called aminoglycosides. They are used to treat severe infections caused by bacteria that can be killed by the active substance gentamicin.
In the treatment of the following infections, except for complicated urinary tract infections, Gentamicin B. Braun is used only in combination with other antibiotics.
Gentamicin B. Braun may be used in the patient for the treatment of the following diseases:

• complicated and recurrent kidney, urinary tract and bladder infections;
• lung and respiratory tract infections occurring during hospital treatment;
• infections in the abdominal cavity, including peritonitis;
• skin and soft tissue infections, also in severe burns;
• sepsis (infection affecting the whole body), bacteria in the blood;
• endocarditis (inflammation of the lining of the heart's inner surfaces);
• post-operative infections.

2. Important information before using Gentamicin B. Braun

When not to use this medicine

• If the patient is allergic to gentamicin, other similar substances or any of the other ingredients of this medicine (listed in section 6).
• If the patient has myasthenia gravis.

Warnings and precautions

Before starting to take this medicine, you should tell your doctor if:

• the patient is pregnant or breastfeeding;
• the patient has kidney function disorders or inner ear deafness;
• if the patient or their mother has a history of a disease related to mitochondrial mutation (genetic disease) or hearing loss caused by the use of antibiotic drugs, it is recommended to inform the doctor or pharmacist before taking an aminoglycoside; some mitochondrial mutations may increase the risk of hearing loss after taking this medicine. Before administering Gentamicin B. Braun, the doctor may recommend genetic testing.
  Then the patient will receive gentamicin only if the doctor considers it necessary for the treatment of the disease. The doctor will pay special attention to the proper selection of the gentamicin dose for the patient.
  The doctor will exercise special caution if the patient has any disease affecting the function of nerves and muscles, such as Parkinson's disease, or if the patient is taking muscle relaxants at the same time, as gentamicin may have a inhibitory effect on nerve and muscle function.
  If the patient experiences severe diarrhea, they should tell their doctor or pharmacist.
  The infection may not respond to gentamicin administration if it did not respond to other aminoglycosides; the patient may experience an allergic reaction to gentamicin if they have previously been allergic to other aminoglycosides.
  Experience with once-daily gentamicin administration is limited in elderly patients.
  To reduce the risk of ear or kidney damage, the doctor will:

• monitor hearing, balance and kidney function before starting, during and after treatment;
• dosage strictly taking into account kidney function;
• in patients with kidney function disorders - taking into account the dose of the antibiotic administered locally in the overall dosage;
• monitoring the concentration of gentamicin in serum during treatment, if necessary in a given case;
• additional checks of the balance and hearing organs in patients with previously existing inner ear damage (hearing or balance disorders) or during long-term treatment;
• whenever possible, administering gentamicin for no longer than 10-14 days (usually 7-10 days);
• re-administering gentamicin or another antibiotic derivative no earlier than 7-14 days after the end of treatment;
• avoiding the simultaneous use of other substances that may damage the auditory nerve or kidneys; if this is unavoidable, it is necessary to carefully monitor kidney function;
• ensuring adequate fluid intake to maintain proper urine production.

Gentamicin B. Braun and other medicines

You should tell your doctor about all medicines that the patient is taking or has recently taken, as well as any medicines that the patient plans to take.
Caution should be exercised when using the following medicinal products.
Muscle relaxants and ether
The inhibition of nerve conduction by aminoglycosides is enhanced by ether and muscle relaxants. Therefore, patients receiving these substances will be monitored with special care.
Methoxyflurane anesthesia
Before starting methoxyflurane anesthesia (anesthetic gas), the anesthesiologist should be informed that the patient is taking aminoglycosides, so that, if possible, the use of this agent can be avoided, due to the increased risk of kidney damage.
Other medicines that may damage hearing or kidneys
The patient will be monitored with special care if they are taking gentamicin before, during or after the use of medicinal products containing the following substances:

• amphotericin B (in fungal infections),
• colistin (for intestinal disinfection),
• cyclosporine (to suppress immune system symptoms),
• cisplatin (anticancer drug),
• vancomycin, streptomycin, viomycin, carbenicillin, other aminoglycosides, cephalosporins (antibiotics). If the patient is taking diuretic drugs, such as ethacrynic acid or furosemide, they will also be closely monitored.

Pregnancy and breastfeeding

Pregnancy
If the patient is pregnant or breastfeeding, suspects that she may be pregnant or plans to have a child, she should consult a doctor before taking this medicine. This medicine should not be used during pregnancy, unless it is absolutely necessary.
Breastfeeding
If the patient is breastfeeding, she should tell her doctor. The doctor will carefully consider whether to stop breastfeeding or administering gentamicin.

Driving and using machines

Caution is recommended when driving vehicles and operating machines, due to the possibility of side effects such as dizziness or balance disorders.

Gentamicin B. Braun contains sodium

[Gentamicin B. Braun 1 mg/ml]
The medicine contains 283 mg of sodium (the main component of common salt) in each bottle.
This corresponds to 14.2% of the maximum recommended daily intake of sodium in the diet for adults.
[Gentamicin B. Braun 3 mg/ml]
The medicine contains 283/425 mg of sodium (the main component of common salt) in each 80/120 ml bottle.
This corresponds to 14.2%/21.3% of the maximum recommended daily intake of sodium in the diet for adults.

3. How to use Gentamicin B. Braun

Dosage in patients with normal kidney function

Adults and adolescents

The recommended daily dose in adolescents and adults with normal kidney function is 3 to 6 mg/kg body weight, administered in one dose (recommended) or in two divided doses.
Usually, treatment does not last longer than 7-10 days, only the treatment of acute and complicated infections may last longer than 10 days.
Measurements of gentamicin concentration in the patient's blood will be performed - blood samples will be taken just before the administration of the next dose and immediately after the end of the infusion, mainly to monitor kidney function. The dose size will be carefully selected to avoid kidney damage.

Children

The daily dose in newborns is 4-7 mg/kg body weight. Newborns are given the required dose in a single daily dose.
The daily dose in infants after the first month of life is 4.5-7.5 mg/kg body weight in a single dose (recommended) or two divided doses.
The recommended daily dose in older children with normal kidney function is 3 to 6 mg/kg body weight per day, administered in one dose (recommended) or in two divided doses.

Dosage in patients with kidney function disorders

If the patient has kidney function disorders, controls will be performed to properly select the therapeutic concentration in the blood, which is achieved either by reducing the dose or increasing the intervals between doses. The attending physician knows how to select the appropriate dosage regimen.

Dosage in dialyzed patients

In this case, the doctor will carefully adjust the dose size based on the gentamicin concentration in the blood.
Elderly patients- due to impaired kidney function, it may be necessary to administer lower maintenance doses than in younger adults.
Obese patients- the initial dose is selected based on ideal body weight plus 40% of excess weight.
Patients with impaired liver function- there is no need to modify the dose.

Overdose of Gentamicin B. Braun

If accumulation of the medicine occurs (e.g. due to improper kidney function), additional kidney or auditory nerve damage may occur.
Procedure in case of overdose
First of all, the administration of the medicine should be stopped. There is no specific antidote (antidote). Gentamicin can be removed from the blood through hemodialysis. If a neuromuscular block occurs, calcium chloride can be administered and, if necessary, assisted breathing can be used.

Method of administration

Gentamicin B. Braun is administered by intravenous infusion (intravenous infusion). The infusion solution contained in the polyethylene bottle is administered over a period of 30-60 minutes.
The Gentamicin B. Braun infusion solution is not intended for intramuscular administration or slow intravenous injection (intramuscular or intravenous injections).
If you have any further questions about the use of this medicine, you should ask your doctor or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
Under certain conditions, gentamicin shows toxic effects on hearing and kidneys. Kidney function disorders are often observed in patients treated with gentamicin and usually disappear after the medicine is discontinued. In most cases, it is related to the administration of too high a dose or prolonged treatment, previously existing kidney function disorders or the simultaneous use of other substances toxic to the kidneys. Additional risk factors for toxic effects on the kidneys are: old age, low blood pressure, reduced blood volume, shock or liver disease. Risk factors for toxic effects on the auditory nerve are: liver disease, hearing disorders, bacteria in the blood, fever.
The following side effects, which may occur very rarely, i.e. less often than in 1 in 10,000 patients, may be severe and may require immediate treatment:

• severe acute hypersensitivity reactions (allergy);
• acute kidney failure.

Symptoms of acute hypersensitivity may include: skin rash, itching and difficulty breathing.
Symptoms of acute kidney failure are: reduced or stopped urine excretion (oliguria, anuria), excessive urine excretion at night and generalized edema (fluid retention in the body).

Infections and infestations

Unknown (frequency cannot be determined based on available data)
Infections caused by other bacteria, resistant to gentamicin. Diarrhea with or without blood and (or) abdominal cramps.

Blood and lymphatic system disorders

Uncommon (may occur in 1 to 10 out of 1,000 patients)
Abnormal blood count
Rare (may occur in 1 to 10 out of 10,000 patients)
Too low a number of different types of blood cells, increased number of eosinophils (a specific type of white blood cell)

Immune system disorders

Unknown (frequency cannot be determined based on available data)
Allergic reactions (including severe ones, such as anaphylaxis), which may include:

• itchy, lumpy rash or urticaria (hives)
• swelling of hands, feet, ankles, face, lips or throat, which may cause difficulty swallowing or breathing
• fainting, dizziness, feeling of dizziness (low blood pressure)

Metabolism and nutrition disorders

Rare (may occur in 1 to 10 out of 10,000 patients)
Low levels of potassium, calcium and magnesium in the blood (related to the use of high doses for a long time), loss of appetite, weight loss
Very rare (may occur less often than in 1 in 10,000 patients)
Low levels of phosphates in the blood (related to the use of high doses for a long time)

Psychiatric disorders

Very rare (may occur less often than in 1 in 10,000 patients)
Confusion, hallucinations, depression

Nervous system disorders

Rare (may occur in 1 to 10 out of 10,000 patients)
Peripheral nerve damage, disorders or loss of sensation
Very rare (may occur less often than in 1 in 10,000 patients)
Organic brain diseases, seizures, neuromuscular blockade, dizziness, balance disorders, headache

Eye disorders

Very rare (may occur less often than in 1 in 10,000 patients)
Visual disturbances

Ear and labyrinth disorders

Very rare (may occur less often than in 1 in 10,000 patients)
Auditory nerve damage, hearing loss, Meniere's disease, ringing or buzzing in the ears, dizziness of peripheral origin
Unknown (frequency cannot be determined based on available data)
Auditory nerve damage, hearing loss

Cardiac disorders

Very rare (may occur less often than in 1 in 10,000 patients)
Low blood pressure, high blood pressure

Gastrointestinal disorders

Rare (may occur in 1 to 10 out of 10,000 patients)
Nausea, vomiting, increased salivation, oral mucositis

Hepatobiliary disorders

Rare (may occur in 1 to 10 out of 10,000 patients)
Transient increased activity of liver enzymes and bilirubin levels in the blood

Skin and subcutaneous tissue disorders

Uncommon (may occur in 1 to 10 out of 1,000 patients)
Allergic skin rash, itching
Rare (may occur in 1 to 10 out of 10,000 patients)
Redness of the skin
Very rare (may occur less often than in 1 in 10,000 patients)
Hair loss, severe allergic reaction of the skin and mucous membranes with blistering and redness of the skin (erythema multiforme
Unknown (frequency cannot be determined based on available data)
Severe allergic reaction of the skin and mucous membranes with blistering and redness of the skin, which may involve other organs and be life-threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis)

Musculoskeletal and connective tissue disorders

Rare (may occur in 1 to 10 out of 10,000 patients)
Muscle pain
Very rare (may occur less often than in 1 in 10,000 patients)
Muscle tremors (making it difficult to maintain a standing position or coordinate movements)

Renal and urinary disorders

Common (may occur in 1 to 10 out of 100 patients)
Kidney function disorders (usually disappear after the end of treatment)
Rare (may occur in 1 to 10 out of 10,000 patients)
Increased levels of urea in the blood (transient)
Very rare (may occur less often than in 1 in 10,000 patients)
Acute kidney failure, high levels of phosphates and amino acids in the urine (a sign of so-called acquired Fanconi syndrome associated with long-term administration of high doses of the medicine)

General disorders and administration site conditions

Rare (may occur in 1 to 10 out of 10,000 patients)
Increased body temperature
Very rare (may occur less often than in 1 in 10,000 patients)
Pain at the injection site

If you experience any side effects, including those not listed in this leaflet

you shouldtell your doctor, pharmacist or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help gather more information on the safety of this medicine.

5. How to store Gentamicin B. Braun

The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the bottle and carton after: "Expiry date". The expiry date refers to the last day of the given month.
No special storage precautions for the medicine.
The solution should be used immediately after opening.
The medicinal product is intended for single use only. Use only if the solution is clear, colorless and does not contain solid particles.
Dispose of any unused solution.

6. Contents of the packaging and other information

What Gentamicin B. Braun contains

• The active substance of the medicine is gentamicin

Solution for infusion 1 mg/ml
1 ml of Gentamicin B. Braun solution for infusion contains 1 mg of gentamicin in the form of gentamicin sulfate.
1 bottle of 80 ml contains 80 mg of gentamicin

• Other ingredients of the medicine are: sodium chloride, water for injections.

Solution for infusion 3 mg/ml
1 ml of Gentamicin B. Braun solution for infusion contains 3 mg of gentamicin in the form of gentamicin sulfate.
1 bottle of 80 ml contains 240 mg of gentamicin.
1 bottle of 120 ml contains 360 mg of gentamicin

• Other ingredients of the medicine are: disodium edetate, sodium chloride, water for injections.

What Gentamicin B. Braun looks like and what the pack contains

Gentamicin B. Braun is a solution for infusion; this means that it is administered in a drip through a thin tube or cannula inserted into a vein.
The solution is clear and colorless.
Gentamicin B. Braun, 1 mg/ml, solution for infusion is contained in polyethylene bottles (Ecoflac plus) with a capacity of 80 ml.
The medicine is supplied in packs containing 10 or 20 bottles.
Gentamicin B. Braun, 3 mg/ml, solution for infusion is contained in polyethylene bottles (Ecoflac plus) with a capacity of 80 and 120 ml.
Both capacities are supplied in packs containing 10 or 20 bottles.

Marketing authorization holder and manufacturer

Marketing authorization holder

• B. Braun Melsungen AG Carl-Braun-Straße 1 Mailing address: 34212 Melsungen, Germany 34209 Melsungen, Germany

Phone: +49/5661/71-0
Fax: +49/5661/71-4567
Manufacturer

• B. Braun Medical S. A. Carretera de Terrassa 121 08191 Rubí (Barcelona), Spain

In order to obtain more detailed information, you should contact the representative of the marketing authorization holder:
Aesculap Chifa Sp. z o.o.
ul. Tysiąclecia 14
64-300 Nowy Tomyśl
Phone: (61) 44 20 100
This medicine is authorized for marketing in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Austria
Gentamicin B. Braun 1 mg/ml Infusionslösung
Gentamicin B. Braun 3 mg/ml Infusionslösung
Belgium
Gentamycine B. Braun 1 mg/ml Solution pour perfusion/Infusionslösung/Oplossing voor infusie YES Pharmaceutical Development Services
Gentamycine B. Braun 3 mg/ml Solution pour perfusion/Infusionslösung/Oplossing voor infusie
Czech Republic
Gentamicin B. Braun
Denmark
Gentamicin B. Braun
Iceland
Gentamicin B. Braun 1 mg/ml innrennslislyf, lausn
Gentamicin B. Braun 3 mg/ml innrennslislyf, lausn
Italy
Gentamicina B. Braun 1 mg/ml soluzione per infusione
Gentamicina B. Braun 3 mg/ml soluzione per infusione
Luxembourg
Gentamicin B. Braun 1 mg/ml Infusionslösung
Gentamicin B. Braun 3 mg/ml Infusionslösung
Norway
Gentamicin B. Braun 1 mg/ml infusjonsvæske, oppløsning
Gentamicin B. Braun 3 mg/ml infusjonsvæske, oppløsning
Poland
Gentamicin B. Braun
Gentamicin B. Braun
Portugal
Gentamicina B. Braun 1 mg/ml Solução para perfusão
Gentamicina B. Braun 3 mg/ml Solução para perfusão
Slovenia
Gentamicin B. Braun 1 mg/ml raztopina za infundiranje
Gentamicin B. Braun 3 mg/ml raztopina za infundiranje
Slovakia
Gentamicin B. Braun 1 mg/ml infúzny roztok
Gentamicin B. Braun 3 mg/ml infúzny roztok
United Kingdom (Northern Ireland)
Gentamicin 1 mg/ml solution for infusion
Gentamicin 3 mg/ml solution for infusion

Date of last revision of the leaflet: 05/2024

_______________________________________________________________________________________

Other sources of information

Detailed information about this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products | (urpl.gov.pl)

Information intended exclusively for healthcare professionals

The Gentamicin B. Braun solution for infusion is ready to use and should not be diluted before administration.
Under no circumstances should aminoglycosides be mixed in a solution for infusion with beta-lactam antibiotics (e.g. penicillins, cephalosporins), erythromycin or lipofundin (a special emulsion of the oil-in-water type for parenteral nutrition), as physical and chemical inactivation may occur. This also applies to the combination of gentamicin with diazepam, furosemide, flecainide acetate or sodium heparin.
Active substances or solutions for dissolution or dilution that should not be administered simultaneously:
gentamicin is incompatible with amphotericin B, cefalotin sodium, sodium nitrofurantoin and tetracyclines.
Adding gentamicin to solutions containing bicarbonate may lead to the release of carbon dioxide.
From a microbiological point of view, the product should be used immediately. If the medicine is not used immediately, the user is fully responsible for the storage time after opening and the conditions prevailing before use, usually no longer than 24 hours at a temperature of 2 to 8°C.
The solution should be administered using a sterile infusion set, using aseptic technique.
The infusion set should be filled with the solution to prevent air from entering the system.
For single use only.
Residual unused solution should be discarded.
Before administration, the solution should be inspected for particles or discoloration. The solution can only be used if it is clear and does not contain any particles.